Trial ID or NCT#

NCT00568490

Status

RECRUITING

Purpose

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Official Title

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Quynh-Thu Le, MD, FACR, FASTRO
Radiation oncologist
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology-Head and Neck Surgery
John B. Sunwoo
Head and neck surgical oncologist, Head and neck surgeon, Cutaneous oncology specialist, Dermato-oncology specialist, Thyroid and parathyroid surgeon, Surgical oncologist
Associate Professor of Otolaryngology - Head and Neck Surgery and, by courtesy, of Dermatology
Richard Goode
Harlan Pinto
Medical oncologist, Head and neck specialist
Associate Professor of Medicine (Oncology) at the Palo Alto Veterans Affairs Health Care System and, by courtesy of Otolaryngology - Head & Neck Surgery at the Stanford University Medical Center
Billy W. Loo, Jr., MD, PhD, DABR
Radiation oncologist, Thoracic specialist
Associate Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Amanda Simmons
(650) 724-4606